

CUMULATIVE INDEX 1996

Volume 14

February	CHANGING THE NATURAL HISTORY OF CORONARY ARTERY DISEASE: RISK FACTORS AND THEIR MODIFICATION, pages 1-173
May	TRIGGER AND TIMING OF CARDIAC EVENTS, pages 175-326
August	DIAGNOSIS AND MANAGEMENT OF INFECTIVE ENDOCARDITIS, pages 327-470
November	ATRIAL FIBRILLATION, pages 471-653

Note: Page numbers of article titles are in **boldface** type

- Ablation, for atrial fibrillation and flutter, 478, 480. See also *Fibrillation, atrial, atrioventricular junctional ablation for* and *Fibrillation, atrial, catheter ablation for*.
- Abortion, infective endocarditis and, 332, 336
- Abscess(es), in infective endocarditis, 427, 431
brain, 434
detection of, 374, 375, 379, 440, 441
incision and drainage of, 335, 336
- Acinetobacter* species, in infective endocarditis, 408, 409
- Acne, infective endocarditis and, 335, 387
- Acquired immunodeficiency syndrome (AIDS), infective endocarditis in, 417
- Actinobacillus actinomycetemcomitans*, in infective endocarditis, 354, 410
- Activation space constant, in atrial fibrillation, 499
- Adenoidectomy, infective endocarditis and, 330, 335
- Aerococcus urinae*, in infective endocarditis, 413
- Alcohol, in atrial fibrillation, 502
in heart disease, 73-76
beverage type and, 75, 76
epidemiologic studies of, 73, 74
mechanisms of, 74, 75
- Alcoholism, infective endocarditis and, 353
- Amiodarone, for atrial fibrillation, 513, 514, 532, 533, 624
- Amoxicillin, to prevent infective endocarditis, 334, 336
- Ampicillin, to prevent infective endocarditis, 334
- Aneurysm(s), mycotic, in infective endocarditis, 430, 431, 434, 448
- Anger, arrhythmias induced by, 293
animal studies of, 293-299
human studies of, 293
impact of on cardiac electrical properties in normal and ischemic heart, 298, 299
impact of on coronary hemodynamic function, 297
in patients with coronary heart disease, life-threatening cardiovascular consequences of, 289-304
ischemia induced by, 292, 293
animal studies of, 293-299
human studies of, 292, 293
lethal physiologic characteristics of, 303, 304
myocardial infarction precipitated by, epidemiologic studies of, 289-292
personality type as factor in, 291, 292
myocardial ischemia following, 297, 298
- Angina pectoris, stable, prognosis of, 224
triggers in, 180
- Angiographic trials, coronary, of cholesterol-lowering therapy, 38-42
of multifactorial risk reduction therapy, 40, 43, 44
relationship between low-density lipoprotein cholesterol and outcome of, 44, 45
- Angiography, comparison of autopsy and natural history studies with, 223, 224
infective endocarditis and, 332
limitations of in determining degree of stenosis, 223, 224
to show progression of coronary artery disease, 224, 225
- Anomaly(ies) of coronary arteries, congenital, as cause of exercise-related sudden death in young athletes, 200, 201
- Antiarrhythmic drugs, for atrial fibrillation, 507-517, 521-534. See also specific names of drugs, e.g., *Quinidine*.
cellular targets of, 508, 509
classification of, 508, 509
electrophysiology and, 508, 509
evaluation of, 509
limitations of, 516, 517
mechanisms of action of, 478, 479, 508, 509
staged care approach to, 515, 516
in prevention of sudden cardiac death, 190, 191
- Antibiotics, prophylactic, for infective endocarditis, 332-337
- Anticoagulation therapy, for cardioversion in atrial fibrillation, 538
- Antioxidants in heart disease, 76-79
basic research in, 76
human observational data in, 76, 77
randomized trials of, 77-79
- Aorta, coarctation of, risk of infective endocarditis in, 386
rupture of, as cause of sudden cardiac death in young competitive athletes, 201

- Aortic valve(s), bicuspid, risk of infective endocarditis in, 386
stenosis of, and sudden cardiac death, 186
in young competitive athletes, 203
- Arrhythmia(s), anger-induced, animal studies of, 293-299
antifibrillatory influences of vagus nerve activation and, 296, 297
central neuroanatomic basis of, 293, 294
human studies of, 293
role of peripheral autonomic nervous system in, 294-297
sympathetic nervous system influences on, 294, 295
atrial. See also *Fibrillation, atrial* and *Flutter, atrial*.
lessons from animal models of, 471-480
reentrant excitation in, 471, 472
ventricular, determining chronology of, 190
- Artery(ies), coronary, anomalies of, as cause of exercise-related sudden death in young athletes, 200, 201
tunneled, as cause of exercise-related sudden death in young athletes, 204
- Aspergillus* species, in infective endocarditis, 355, 414-416
- Aspirin, effect of on circadian variation of cardiovascular events, 245
in prevention of embolization in chronic atrial fibrillation, 539, 540
versus warfarin, 540
- Atenolol, for heart rate control in atrial fibrillation, 528, 529
- Atherosclerosis, altered endothelial regulation of vasomotion in, 6-11
benefits of exercise for, 85-94
development of exercise prescription for, 90-93
lipid lowering in, 117-128
pathogenic factors in development of, 211, 212
pathophysiology of, 211
plaques in. See *Plaque(s)*.
"regression trials" of, 31-49
background and methodology of, 31-38
coronary progression in, 31-35
coronary regression in, 35, 36
endpoint measurements in, 37, 38
serial coronary arteriograms in, assessment of, 35-37
role of in coronary heart disease, 176-178
role of inflammation in, 212, 213
- Atherosclerosis in Communities (ARIC) Study, 241, 243
- Athlete(s), sudden cardiac death in, 195-207
older, 206, 207
young competitive, 195-206
aortic rupture as cause of, 201
aortic valve stenosis as cause of, 203
arrhythmogenic right ventricular dysplasia as cause of, 203, 204
atherosclerotic coronary artery disease as cause of, 201, 202
blunt impact to the chest as cause of, 205, 206
causes of, 196-206
conduction system abnormalities as cause of, 204
congenital coronary artery anomalies as cause of, 200, 201
definitions of, 195
demographics of, 195, 196
exercise-induced coronary spasm as cause of, 204
hypertrophic cardiomyopathy as cause of, 197, 198-200
long QT syndrome as cause of, 204
mitral valve prolapse as cause of, 202, 203
myocarditis as cause of, 202
primary arrhythmia as cause of, 204
right ventricular dysplasia as cause of, 204
tunneled coronary artery as cause of, 204
with apparently normal hearts, 204
Wolff-Parkinson-White syndrome as cause of, 204
- Atrial fibrillation. See *Fibrillation, atrial*.
- Atrial septal defect(s), infective endocarditis and, 328, 334
- Bacillus cereus*, in infective endocarditis, 354
- Back pain, in infective endocarditis, 356
- Bacteria, in infective endocarditis. See also names of specific bacteria, e.g., *Staphylococcus aureus*.
anaerobic, 354, 411
enterococci, 353, 385, 386, 416
gram-negative, 354, 386
gram-positive, 354
staphylococci, 353, 354, 385
streptococci, 353, 385, 386
- Bacteroides fragilis*, in infective endocarditis, 354, 411, 412
- Barium enema, infective endocarditis and, 331, 336
- Bartonella (Rochalimaea) quintana*, in infective endocarditis, 354
- Bartonella* species, in infective endocarditis, 412, 413
- Beta Blocker Heart Attack Trial (BHAT), 190
- Beta-blocking agents. See also specific names, e.g., *Propranolol*.
after myocardial infarction, prevention of death by, 190
for heart rate control in atrial fibrillation, 524, 528, 529
acute, 528
during exercise, 528, 529
guidelines for therapy with, 530, 531
paroxysmal, 529
resting, 528
- BHAT (Beta Blocker Heart Attack Trial), 190
- Bite(s), animal and insect, infective endocarditis and, 387
- Blalock-Taussig shunt(s), infective endocarditis and, 329
- Blindness, sudden, in infective endocarditis, 356
- Blood pressure, changes in. See *Hemodynamic changes*.
- Blunt impact to chest as cause of exercise-related sudden death in young athletes, 205, 206
- Bowel disease, inflammatory, infective endocarditis and, 418
- Branhamella catarrhalis*, in infective endocarditis, 413
- Bronchoscopy, infective endocarditis and, 330, 335
- Brucella* species, in infective endocarditis, 354, 357, 411
- Brucellosis. See *Brucella species*.
- Burn(s), infective endocarditis and, 329
- Calcium-channel blockers. See also specific names, e.g., *Verapamil*.
for heart rate control in atrial fibrillation, 524, 529-531
acute, 529
daily, 529, 530
effects of during paroxysmal atrial fibrillation, 530
effects of on exercise duration and tolerance, 530
guidelines for therapy with, 530, 531
- Campylobacter fetus*, in infective endocarditis, 409
- Candida* species, in infective endocarditis, 355, 414-416
- Capnocytophaga canimorsus*, in infective endocarditis, 411
- Carbon monoxide production by cigarette smokers, 54
- Cardiac Arrhythmia Suppression Trial (CAST), 187-191
- Cardiac death, sudden. See *Death, cardiac, sudden*.

- Cardiac lesion(s), type of, in stratification of risk of endocarditis, 334, 335
- Cardiac surgery, atrial fibrillation following, 501
- atrial flutter following, 579, 580
- infective endocarditis and, 327, 332, 336
- Cardiobacterium hominis*, in infective endocarditis, 354, 410
- Cardiomyopathy, hypertrophic, in young competitive athletes, 197, 198-200
- infective endocarditis and, 334
- sudden cardiac death in, 186
- Cardiovascular events, acute. See also specific types, e.g., *Myocardial infarction*.
- during life crises and disasters, 273-276
- mechanism of onset of, 239, 240
- stress as trigger of, epidemiologic evidence for, 273-276
- triggering of, prevention and practical aspects of, 309-311
- Cardioversion, in atrial fibrillation, anticoagulation regimen for, 538
- echocardiographic predictors of success of, 544, 545
- guided by transesophageal echocardiography (TEE), 550
- left atrial size and, 544, 545
- prevention of embolism related to, 537, 538
- return of atrial mechanical function after, 538, 549, 550
- transesophageal echocardiography before, 538, 539
- CAST (Cardiac Arrhythmia Suppression Trial), 187-191
- Catheterization, infective endocarditis and, cardiac, 332, 336
- pulmonary artery, 329
- urethral, 331, 336
- valve trauma caused by, 328
- Cautery, nasal, infective endocarditis and, 330, 387
- Cefamandole, to prevent infective endocarditis, 334
- Cefazolin, to prevent infective endocarditis, 333
- Cephalosporin, to prevent infective endocarditis, 337
- Cephalothin, to prevent infective endocarditis, 334
- Cerebrospinal fluid, abnormalities of, in infective endocarditis, 434
- Cervix, biopsy of, infective endocarditis and, 332
- Chest, blunt impact to, as cause of exercise-related sudden death in young athletes, 205, 206
- Childbirth, infective endocarditis and, 332, 336
- Children, infective endocarditis in, 386
- prophylaxis for, 389, 390
- Chlamydia, in infective endocarditis, 357
- Cholesterol, low-density lipoprotein (LDL). See *Lipoprotein(s)*.
- serum, role of in heart disease, 70, 71
- Cholesterol-lowering therapy, angina and myocardial ischemia and, 45, 46
- coronary angiographic trials and, 46-48
- coronary events and, 46-49
- new coronary lesions and, 46, 47
- Scandinavian Simvastatin Survival Study of, 48, 49
- Cigarette smoking, and coronary heart disease, 51-65
- management of smoker with, 59, 60, 61
- pathophysiology of, 53-55
- population at risk for, 55, 56
- as trigger of myocardial ischemia, 278
- behavioral treatment programs for, 57
- blood clotting and, 54, 55
- cessation of, 56
- barriers to, 56, 57
- behavioral factors and, 56
- health benefits of, 52, 53
- mood disorders and, 56, 57
- nicotine dependency and, 56
- primary prevention of coronary heart disease and, 52
- secondary prevention of coronary heart disease and, 53
- treatment to promote, 57-59
- weight gain and, 57
- health risks of, 51, 52
- metabolic effect of, 55
- hemodynamic changes caused by, 233
- nicotine replacement therapy in, 57-59
- passive, effects of, 55
- systemic effects of, 53, 54
- vascular effects of, 54
- Circadian patterns, in efficacy of thrombolytic therapy, 252-256
- in tachycardia, 190
- in thrombolytic and antithrombotic activities, 251-261
- more lysis versus less thrombosis in, 252
- in thrombolytic and antithrombotic potential, 256-259
- of coronary heart disease, epidemiologic aspects of, 175-183
- pharmacologic agents affecting, 182, 183
- of hemostatic factors, 243-245
- of strokes, 179, 180
- of sudden cardiac death, 185-193
- therapeutic implications of, 190, 191
- Cirrhosis, infective endocarditis and, 329
- Clonidine in treatment of nicotine withdrawal, 59
- Clostridium* species, in infective endocarditis, 412, 413
- Clubbing of fingers, in infective endocarditis, 432
- Cold weather, hemodynamic changes caused by, 233
- Collagen vascular disease(s), infective endocarditis and, 329
- Colonoscopy, infective endocarditis and, 331, 336
- Commotio cordis as cause of exercise-related sudden death in young athletes, 205, 206
- Conduction, cardiac, abnormalities of, as cause of sudden cardiac death in young competitive athletes, 204
- as complication of infective endocarditis, 428
- anisotropic, reentrant excitation and, 484-486
- Congenital heart disease, infective endocarditis in, 328, 329, 351, 383-390
- clinical diagnosis of, criteria for, 384, 385
- clinical manifestations of, 387, 388
- echocardiography in, 388
- microbiology of, 385, 386
- pathogenesis of, 383, 384
- predisposing lesions and risk factors in, 386, 387
- prophylaxis for, 389, 390
- surgical intervention for, 389
- treatment of, 388, 389
- Contraceptive device(s), intrauterine, infective endocarditis and, 332, 336, 337
- Coronary artery(ies), angiographic morphology of, following myocardial infarction, 225, 226
- anomalies of, as cause of exercise-related sudden death in young athletes, 200, 201
- Coronary artery disease, angiographic progression of, 224, 225
- as cause of sudden death in older athletes, 206, 207
- atherosclerotic, as cause of sudden cardiac death in young competitive athletes, 201
- barriers to lifestyle changes in, 159-168
- of cardiologists, 167
- of patients, 160-162
- physician-specific, 162-165
- systemic, 165-167
- effect of estrogens and menopause on, 105-114

Coronary artery disease (*Continued*)

- angiographic studies of, 107, 108
- balancing risks and benefits of estrogen replacement therapy and, 113, 114
- cardioprotective mechanisms, 111-113
- community-based case-control studies of, 106, 107
- endothelial cell function and, 113
- epidemiologic studies of, 105, 106
- hospital-based case-control studies of, 106
- in natural versus surgically induced menopause, 111
- lipoprotein metabolism and, 111-113
- meta-analysis of, 110, 111
- primary versus secondary prevention and, 111
- prospective cohort studies of, 108-110
- prevention of, integrated approach to, 159-168
- risk factor modification in, difficulty of implementation of, 143
- MULTIFIT system of, 143-156
- Coronary Artery Surgery Study (CASS), 224
- Coronary flow deficits during REM sleep, 300, 301
- Coronary heart disease, anger in patients with, life-threatening cardiovascular consequences of, 289-304
- atherosclerosis and, 176-178
- circadian variation in onset of, 178-183
- natural history of, 176-178
- psychosocial risk factors in, 97-102
 - affecting biobehavioral mechanisms in, 99
 - antidepressive agents in treatment of, 101
 - bupropion in reduction of Type A behavior and, 101
 - interventions to reduce impact of on prognosis, 99-102
 - social support and stress-management skills in reduction of, 99, 100
 - response-to-injury hypothesis of, 176
- Corynebacterium* species, in infective endocarditis, 354, 406, 419
- Coxiella burnetii*, in infective endocarditis, 357, 411
- Crises, life, as triggers of acute cardiovascular events, 273, 274
- Cryptococcus* species, in infective endocarditis, 417
- Curvularia* species, in infective endocarditis, 416
- Day of the week, influence of on occurrence of acute cardiac events, 192, 193
- Death, cardiac, sudden, antiarrhythmic drugs in prevention of, 190, 191
 - circadian patterns and triggers of, 185-193
 - clinical correlation in, 187-189
 - day-of-the-week patterns of occurrence of, 192, 193
 - definition of, 185, 186
 - dreams as behavioral triggers of, 299-303
 - human studies of, 301-303
 - implantable cardioverter defibrillator in studies of, 190
 - in atherosclerotic coronary artery disease, 186
 - in athletes, older, 206, 207
 - triggers of, 195-207
 - young competitive, 195-206
 - in obstructive hypertrophic cardiomyopathy, 186
 - in valvular aortic stenosis, 186
 - pathology of, 186
 - pathophysiology of, 186, 187
 - physical exertion as trigger of, 263-269
 - risk of during heavy physical exertion, 265-267
 - mechanism of, 267, 268

- triggers of, 180
 - in the athlete, 195-207
 - prevention and practical aspects of, 309-311
 - without atherosclerotic coronary artery disease, 186

Decision analysis, 624-629

- in atrial fibrillation, 628, 629
 - and randomized, controlled trials, 637
 - baseline analysis in, 630-632
 - cost-effectiveness analysis in, 635
 - limitations of, 632, 634-637
 - methodology of, 629, 630
 - paroxysmal, 635, 636
 - sensitivity analysis in, 632-634
 - warfarin versus antiarrhythmic therapy for, 629-632

Defibrillation, atrial, 607-620

- effects of on atrial myocardium and the coronary sinus, 616, 617
- efficacy of, 608-610
 - animal studies of, 608-610
- electrode configuration in, 611-614
 - animal studies of, 611
 - human studies of, 611, 612
- electrode size in, 612, 613
- internal, techniques and indications for, 617, 618
- pain in, 616
- safety of, 614-616
 - for bradyarrhythmias, 616
 - for tachyarrhythmias, 614-616
- shock waveform in, 613, 614
- with implantable defibrillator, 618-620

Delirium cordis, 483

Dental hygiene, infective endocarditis and, 335

Dental procedures, infective endocarditis and, 329, 330, 333, 335, 336, 385

Diabetes mellitus, infective endocarditis and, 329, 353

Dialysis, renal, infective endocarditis and, 455

Diathesis, endocarditis, 329, 334

Diet and heart disease, 69-79

- role of alcohol in, 73-76
 - beverage type and, 75, 76
 - epidemiologic studies of, 73, 74
 - mechanisms of, 74, 75
- role of antioxidants in, 76-79
 - basic research on, 76
 - human observational data on, 76, 77
 - randomized trials on, 77-79
- role of fat in, 70-73
 - fish oils and, 73
 - human observations and randomized trial data on, 71, 72
 - trans-fatty acids and, 72, 73
- serum cholesterol and, 70, 71
- Digoxin, for control of heart rate in atrial fibrillation, 524, 525-528
 - acute, 525, 526
 - exertional, 526, 527
 - guidelines for therapy with, 530, 531
 - long-term, 526
 - magnesium and, 526
 - paroxysmal, 527, 528
- Dilation and curettage, infective endocarditis and, 332, 336
- Diltiazem, for control of heart rate in atrial fibrillation, 524, 529-531
- Diphtheroids, in infective endocarditis, 354
- Disasters, natural, as trigger of acute cardiovascular events, 275
 - hemodynamic changes caused by, 233
- Disopyramide, for atrial fibrillation, 511

- Doppler echocardiography, in infective endocarditis, 376
- Dreams, as behavioral triggers of ischemia and sudden death, 299-303
- coronary flow deficits during, 300, 301
- Drug abuse, infective endocarditis and, 329
- intravenous, 327, 358-360, 408, 416, 417
- Ductus arteriosus, patent, infective endocarditis and, 334, 386
- Duodenum, endoscopy of, infective endocarditis and, 330
- Echocardiography, in detection of vegetations of
- infective endocarditis, 440
 - false-positive, 373
 - M-mode, 363, 364
 - prognostic implications of, 377-379
 - size of, 377-379
 - two-dimensional, 364-372
- in evaluation and management of atrial fibrillation, 543-551
- in infective endocarditis, 327
- detection of vegetations and embolic events by, 440
 - Doppler, 376
 - role of in selection of patients for surgical intervention in, 439-442
- transesophageal. See *Transesophageal echocardiography (TEE)*.
- transthoracic. See *Transthoracic echocardiography (TTE)*.
- two-dimensional, size of vegetations and, 377, 378
- Eikenella corrodens*, in infective endocarditis, 354, 410
- Electrical properties, cardiac, impact of anger on in normal and ischemic heart, 298, 299
- Embolic disease, focal, 435
- Embolus (emboli) formation, in infective endocarditis, 430
- cerebral, 433, 434
 - surgical treatment of, 453, 454
- Endocarditis, infective, 327-339
- abortion and, 332
 - abscesses in, 440, 441
 - brain, 434
 - detection of, 374, 375, 379, 440, 441
 - adenoidectomy and, 330
 - anaerobic bacteria in, 354, 411, 412
 - angiography and, 332
 - animal models of, 328
 - arteriovenous shunts, iatrogenic, and, 329
 - atrial septal defect and, 328
 - average age of patients with, 352
 - barium enema and, 331
 - Beth Israel study of, 346
 - Blalock-Taussig shunts and, 329
 - blood cultures for, 356, 357
 - bronchoscopy and, 330
 - burns and, 329
 - cardiac surgery and, 332, 337
 - catheterization and, cardiac, 332
 - pulmonary arterial, 329
 - urethral, 331
 - causative organisms of, 352-355, 397-414. See also names of specific organisms, e.g. *Streptococcus viridans*.
 - caveats and unanswered questions about, 337, 338
 - cefamandole for, 334
 - cefazolin for, 333
 - cephalothin for, 334
 - cervical biopsy and, 332
 - chemoprophylaxis for, 332-337
 - in certain procedures, 335, 336
 - selection of regimens of, 336, 337
 - cirrhosis and, 329
 - clinical approach to, 351-360
 - clinical manifestations of, 345-349, 355, 356
 - cardiac, 355
 - cutaneous, 356
 - musculoskeletal, 356
 - ophthalmologic, 356
 - clinical profile of, changes in, 327
 - clubbing of fingers in, 432
 - collagen vascular diseases and, 329
 - colonoscopy and, 331
 - complications of, 377
 - abscesses as, 431, 434
 - cardiac, 425-429
 - cardiac, cerebral, and vascular, 425-436
 - cerebral embolism as, 433, 434
 - cerebrospinal fluid abnormalities as, 434
 - conduction system abnormalities as, 428
 - cutaneous, 431
 - detection of, 374-377
 - diagnosis of, 363
 - embolus formation as, 430
 - extracardiac, 430, 432
 - heart failure as, 432, 433
 - mycotic aneurysm as, 430, 431, 434
 - myocardial disease as, 427, 428
 - neurologic, 433-435
 - pericardial disease as, 429
 - peripheral vascular, 430
 - persistent fever as, 435, 436
 - petechiae as, 431
 - renal disease as, 435
 - seizures as, 434
 - solid organ, 431, 432
 - splinter hemorrhages as, 432
 - valve ring abscess as, 427
 - valvular disease as, 425-427
 - vasculitis as, 431
 - corynebacteria in, 354, 406
 - culture-negative, 393-395
 - death rate in, 327
 - demographics of, 345
 - dental procedures and, 329, 330
 - diabetes mellitus and, 329
 - diagnosis of, 327, 358, 393-396
 - criteria for, revised, 345-349
 - Duke University criteria for, 373, 374, 384, 385
 - role of transesophageal echocardiography in, 363-380
 - role of transthoracic echocardiography in, 363-380
 - von Reyn criteria for, 373, 374, 384, 385
 - dilatation and curettage and, 332
 - diphtheroids in, 354
 - drug addiction and, 327, 329, 358-360, 408, 416, 417
 - Duke University study of, 346-349
 - echocardiography in, 330, 331, 374, 418. See also *Transesophageal echocardiography (TEE)* and *Transthoracic echocardiography (TTE)*.
 - role of in patient selection for surgical intervention for, 439-442
 - endoscopic procedures and, 330, 418
 - enterococcal, prevention of, 334
 - epidemiology of, 351, 352
 - erythromycin for, 333
 - etiology of, 345
 - experimentally induced, 328
 - fever in, 355, 435, 436

Endocarditis (*Continued*)

- fungal, 354, 355, 386, 414-416. See also specific names of fungi, e.g., *Candida* species.
- risk factors for, 414
- gastrointestinal tract procedures and, 330, 331
- genitourinary procedures and, 330, 331
- gentamicin for, 334
- gram-negative bacilli in, 354, 406-409
- gram-positive bacilli in, 354
- gum disease and, 329, 330
- hematologic abnormalities in, 357
- hematologic disorders, nonmalignant, and, 329
- hemodialysis and, 329
- hemodynamic factors that predispose to, 328
- hepatitis, chronic, and, 329
- hyperalimentation and, 329
- immunologic abnormalities in, 357
- immunologic evidence of, 395
- immunologic reactions in, 384
- in acquired immunodeficiency syndrome, 417
- in brucellosis, 354
- in children, diagnosis of, 386
- in congenital heart disease. See *Congenital heart disease, infective endocarditis in.*
- in congestive heart failure, 443, 444
- in degenerative heart disease, 351
- in geriatric patients, 345
- in homeless men, 354
- in human immunodeficiency virus (HIV) infection, 417
- in intravenous drug users, 345, 352, 358-360, 408, 416, 417
 - bacteriology and anatomy of, 359
 - clinical characteristics of, 359, 360
 - diagnosis of, 360
 - mortality in, 360
- in native valves, 442-445, 451, 452
 - complications of, 442, 443
- in previously normal valves, 328
- in prosthetic valves, 345, 429, 445-448, 452
 - early versus late, 446, 447
- inflammatory bowel disease and, 418
- intrauterine contraceptive devices and, 332
- intubation and, 330
- laboratory findings in, 356, 357, 395
- liver biopsy and, 331
- major surgery and, 329
- management of, antibiotic, advances in, 393-419
 - medical, advances in, 393-419
 - role of transesophageal echocardiography in, 363-380
 - role of transthoracic echocardiography in, 363-380
- microorganisms causing, 352-355, 393-396
- mitral valve prolapse and, 334, 335, 351
- mitral-aortic intervalvular fibrosa in, detection of, 375, 376
- naftillin for, 334
- nasal cautery and, 330
- neoplastic diseases and, 329
- neurologic manifestations of, 388
- nonvalvular, detection of, 372, 373
- nosocomial infections in, 452
- obstetric and gynecologic procedures and, 332
- of tricuspid valve, 445
- oral hygiene and, 329, 330
- pacemakers and, 418
- parturition, uncomplicated, and, 332
- pathogenesis of, 327, 328
- patients at risk for, 329
 - high, 334
 - intermediate, 334
 - low, 334
- penicillins for, 333, 334
- pharmacodynamics of antimicrobial therapy for, 396
- pneumococcal, alcoholism and, 353
- diabetes mellitus and, 353
- polymicrobial, 416
- portals of entry for organisms in, 329-332
 - airways and respiratory tract as, 330
 - cardiac catheterization as, 332
 - cardiac surgery as, 332
 - gastrointestinal tract as, 330, 331
 - genitourinary tract as, 331
 - liver biopsy as, 331
 - obstetric and gynecologic procedures as, 332
 - oral cavity as, 329, 330
- postoperative, 329
- predisposing causes and conditions in, 328, 329
- prevention of, 332-337
 - animal model of, 333, 334
 - experimental, 333, 334
- pulmonary artery catheters and, 329, 352
- recurrence of, risk of, 352
- renal failure and, 329
- rifampin for, 334
- right-sided, 419
 - clinical manifestations of, 388
- risk of, stratification of by type of cardiac lesion, 334, 335
- sigmoidoscopy and, 331
- staphylococci in, 404, 405
- Staphylococcus aureus* in, 345-347
- steroids and, 329
- streptococci in, 397-404
 - enterococci, 401-403
 - group B, 400, 401
 - group D, 400
 - nutritionally variant, 401
 - pyogenic, 398-400
- streptomycin for, 333
- subacute versus acute, 327, 328
- surgical intervention in, 439
 - congenital heart lesions and, 454
 - echocardiography in, 455, 456
 - for congestive heart failure, 443-444, 453
 - for embolization, 453, 454
 - for extension, sepsis, and persistent infection, 444, 445
 - for infected pacemaker and defibrillator leads, 448, 449
 - for persistent sepsis, 452, 453
 - for systemic embolism, 445
 - for tricuspid valve infection, 445
 - for valvular abnormalities and dysfunction, 441
 - for vegetations and embolic events, 440
 - in aortic valve, 456-459
 - in immunosuppressed patients, 454, 455
 - in mitral valve, 457-461
 - in mycotic aneurysms, 448
 - in prosthetic valves, 447, 448, 454
 - in renal dialysis patients, 455
 - in tricuspid valve, 461-463
 - indications for, 439-449, 452-455
 - issues in, 451-463
 - operative management during, 456
 - outcomes and future of, 462, 463
 - principles of, 455, 456
 - role of echocardiography in, 439-442
 - transesophageal echocardiography (TEE) and, 453
- Swan-Ganz catheters and, 329, 352

- tonsillectomy and, 330
 transesophageal echocardiography (TEE) and, 330, 331, 418
 transplant-related, 418, 419
 transurethral resection of the prostate and, 331
 treatment of, 327
 outpatient, 396, 397
 trench fever and, 354
 urinary abnormalities in, 357
 urinary tract infection and, 331
 vancomycin for, 333
 vegetations in, 363
 detection of, 363-373, 377-379
 size of, 377-379
 ventricular septal defect and, 328
 Endocarditis diathesis, 329, 334
 Endoscopy, gastrointestinal, risk of infective endocarditis following, 330, 418
 infective endocarditis and, 336
 Endothelial dysfunction, 4-6
 Endothelium, vascular, in regulation of vasomotion, 1-13
 arginine deficiency and, 8
 destruction of nitric oxide by superoxide in, 9-11
 effect of diseases on, 4-7
 future directions for clinical care and, 13
 historical perspective of, 1, 2
 implications of for risk-factor management, 13
 improvement of by treatment of
 hypercholesterolemia, 11-13
 in atherosclerosis and hypercholesterolemia, alterations in, potential mechanisms of, 7-11
 membrane signaling alterations in, 8, 9
 nitric oxide derived from, 2
 nitric oxide synthase alterations in, 9
 Endothelium-derived hyperpolarizing factor, 3, 4
 Endothelium-derived relaxing factor, 2
 Enterobacter cloacae, in infective endocarditis, 419
 Enterobacter species, in infective endocarditis, 354, 407
 Enterobacteriaceae, in infective endocarditis, 406-409
 Enterococcus faecalis, in infective endocarditis, 353, 385, 401, 402
 Enterococcus faecium, in infective endocarditis, 401, 402
 Enterococcus species, in infective endocarditis, 353, 401, 402, 416
 vancomycin-resistant, 402, 403
 Erysipelothrix rhusiopathiae, in infective endocarditis, 354, 406
 Erythromycin, to prevent infective endocarditis, 333
 Escherichia coli, in infective endocarditis, 354, 419
 Esmolol, for heart rate control in atrial fibrillation, 524, 528, 529
 Esophagus, endoscopy of, infective endocarditis and, 330
 Estrogen(s), effect of on coronary artery disease, 105-114
 angiographic studies of, 107, 108
 cardioprotective mechanisms of, 111-113
 case-control studies of, 106, 107
 endothelial cell function and, 113
 lipoprotein metabolism and, 111-113
 meta-analysis of, 110, 111
 prospective cohort studies of, 108-110
 type of menopause and, 111
 Estrogen-replacement therapy, balancing risks and benefits of, 113, 114
 effect of on endothelial cell function, 113
 effect of on lipoprotein metabolism, 111-113
 primary versus secondary, 111
 Estrogens, menopause, and coronary artery disease, 105-114
 Euglobulin fibrinolytic activity, circadian variation in, 258
 European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study (ECAT), 240
 Excitation, reentrant, in atrial arrhythmias, 471, 472
 Exercise, antiatherosclerotic effect of, 85-94
 developing prescription for, 90-93
 studies on, 85-90
 training techniques in, 93, 94
 balancing cardiac risks and benefits of, 268
 prescription for in atherosclerosis, 90-93
 activity classification in, 91-93
 for apparently healthy individuals, 91, 92
 for individuals with known, stable cardiovascular disease with low risk for vigorous exercise, 92
 for individuals with moderate to high risk for cardiac complications during exercise, 92
 for individuals with unstable disease with activity restriction, 92, 93
 to reduce risk of triggering acute coronary events, mechanisms of, 267, 268
 training techniques for, 93, 94
 Exertion, physical, as trigger of myocardial infarction and sudden cardiac death, 263-269
 risk of nonfatal myocardial infarction during, 264, 265
 mechanism of, 267, 268
 risk of sudden cardiac death during, 265-267
 mechanism of, 267, 268
 Exophiala species, in infective endocarditis, 416
 Factor VII as hemodynamic risk factor, 242
 Fat, dietary, role of in heart disease, 70-73
 Fever, in infective endocarditis, 388
 persistent, 435, 436
 Fibrillation, atrial, ablation for, 478, 480. See also Fibrillation, atrial, atrioventricular junctional ablation for and Fibrillation, atrial, catheter ablation for.
 direct, 584-586
 indirect, 584
 activation space constant in, 499
 after cardiac surgery, 501
 amiodarone for, 513, 514, 532, 533
 antiarrhythmic drug therapy for, 507-517, 521-534.
 See also specific names of drugs, e.g., Quinidine.
 cellular targets of, 508, 509
 electrophysiology and, 508, 509
 evaluation of, 509
 limitations of, 516, 517
 mechanisms of action of, 508, 509
 staged care approach to, 515, 516
 as both cause and result, 503
 atrial refractoriness and, age-related, 488, 489
 dispersion of, 486-489
 atrioventricular junctional ablation for, 555-566
 catheter placement in, 557, 561
 catheter selection in, 561
 complications of, 565, 566
 direct current energy in, 555, 556
 energy delivery in, 561
 energy sources for, 555, 556
 escape rhythm after, 564
 future management strategies and, 566
 future techniques of, 565
 hemodynamic and symptomatic effects of, 564, 565
 options after failure of, 562
 patient preparation for, 557, 561
 patient selection for, 556-560
 postablation procedure in, 562

Fibrillation (*Continued*)

- radiofrequency energy in, 556
- results of, 562-564
- success rates of, 563
- technique of, 557, 561
- atrioventricular junctional modification for, 564, 565
- beta-blocking agents for control of heart rate in, 524, 528, 529. See also specific names, e.g., *Propranolol*.
- calcium-channel blockers for control of heart rate in, 524, 529-531. See also specific names, e.g., *Verapamil*.
- cardioversion in. See *Cardioversion in atrial fibrillation*.
- catheter ablation for, 583-588
 - animal models of, 583
 - atrial flutter following, 586, 588
 - background of, 583
 - catheter maze procedure in, 585, 586
 - focal, 585
 - other energy forms in, 588
 - right atrial-only, 586, 587
- chronic, prevention of embolization in, 539-541
- clinical spectrum of, 500-502
- decision analysis in, 623-637
- digoxin for control of heart rate in, 524, 525-528
- disopyramide for, 511
- effects of ablation and surgical lesions on, 479, 480
- electrical remodeling in, 475, 476
- electrophysiologic aspects of, 483-503
 - summary of, 500
 - treatment implications and, 503
- epidemiology of, 507
- flecainide for, 511-513, 532, 533
 - adverse effects of, 512, 513
- heart rate control versus rhythm management in, 507, 508
- heart rate in, optimal, 523, 524
- historical background of, 483
- ibutilide for, 515
- in valvular heart disease, 501
- in Wolff-Parkinson-White syndrome, 489, 490, 501, 502
- initiation of, 592
- magnitude squared coherence spectrum in, 499
- mapping of, 584
 - observations from, 493-495
- measuring organization in, catheter-based strategies for, 495-500
- mechanisms and promoters of, 472-476
- multiple wavelet hypothesis of, 472, 473, 484
 - evidence for, 489-492
 - maze procedure as test of, 492
- pacing strategies to prevent, 591-595
- paroxysmal, autonomic influences in, 502
- pathophysiology in, 500-502
- persistence of, 473-475
- pharmacologic control of, 521-534. See also *Antiarrhythmic drugs for atrial fibrillation* and specific names of drugs, e.g., *Propranolol*.
- prevention of embolization in, aspirin in, 539, 540
 - primary, 539, 540
 - secondary, 540, 541
 - warfarin versus aspirin in, 540
- procainamide for, 510, 511
- propafenone for, 513, 532, 533
- quality of life in patients with, 597-605
 - Ablate and Pace Registry (APT) study of, 603
 - Atrial Fibrillation Follow-Up: Investigation of Rhythm Management (AFFIRM) study of, 603, 604
 - discussion of findings about, 604, 605

- multidimensional assessment of, 600-602
- patient interview to determine, 598-600
- self-reported symptoms and, 600
- studies related to, 598, 599, 603, 604
- quinidine for, 509-511
 - adverse affects of, 510
- rate control in, drug therapy for, 524, 525, 526
 - versus restoration of sinus rhythm in, 623, 624
- reentry as mechanism for, 483, 484
- role of alcohol in, 502
- role of echocardiography in evaluation and management of, 543-551
- sotalol for, 514, 515, 531, 532
- spectrum of behavior of, 492, 493
- therapeutic strategies for, decision analysis and, 623-637
- thromboembolism in, prevention of, 537-541
- transesophageal echocardiography (TEE) in, 544
- types of, 492-495
- ventricular rate in, 521
 - versus atrial flutter, 480
- Fibrinogen as hemodynamic risk factor, 240-242
- Fibrinolysis as hemodynamic risk factor, 242
- Fibrosa, mitral-aortic intervalvular, detection of, 375, 376
- Finger(s), clubbing of, in infective endocarditis, 432
- Fish oils, role of in heart disease, 73
- Flecainide, for atrial fibrillation, 511-513, 532, 533, 624
 - adverse effects of, 512, 513
- Flow deficits, coronary, during REM sleep, 300, 301
- Flutter, atrial, and atrioventricular nodal reentry, 580, 582
 - atypical, 579
 - boundaries in, 477, 478
- catheter ablation for, 569-583
 - atrial arrhythmias following, 579
 - background of, 569, 570
 - future directions in, 582, 583
 - results and measures of efficacy of, 577-579
 - studies of, 574-577
 - temperature and, 579
- circuit anatomy and location in, 570-573
- following cardiac surgery, 579, 580
- left, 580
- mapping studies of, 573-575
- mechanisms and promoters of, 476-478
- pathophysiology of, 570
- primary ablation of, 569-588
- reentrant mechanism for, 471
- versus atrial fibrillation, 480
- Framingham Heart Study, 179, 187
- Fungus (fungi), in infective endocarditis, 354, 355, 386, 414-416
 - Dematiaceae, 416
- Fusobacterium necrophorum*, in infective endocarditis, 354, 412
- Gastrointestinal procedures, infective endocarditis and, 335, 336, 337, 418
- Gemella haemolysans*, in infective endocarditis, 413
- Genitourinary procedures, infective endocarditis and, 330, 331, 335, 336, 337
- Gentamicin, to prevent infective endocarditis, 334
- Gingivitis, infective endocarditis and, 330
- Glomerulonephritis, in infective endocarditis, 384, 435
- Gram-negative bacilli, in infective endocarditis, 354, 406-409
- Gram-positive bacilli, in infective endocarditis, 354

- Gum disease, infective endocarditis and, 329, 330, 335, 387
prevention of, 389
- Gynecologic procedures, infective endocarditis and, 332
- HACEK group of gram-negative bacteria, 354
in infective endocarditis, 399, 409-411
- Haemophilus* species, in infective endocarditis, 354, 409, 410, 417
- Heart, normal, impact of anger on electrical properties of, 298, 299
- Heart failure, in infective endocarditis, 432, 433
congestive, 355, 443, 444
surgical treatment of, 453
- Hematologic disorders, nonmalignant, infective endocarditis and, 329
- Hemodialysis, infective endocarditis and, 329, 334
- Hemodynamic changes, as triggers of cardiovascular events, 229-237
clinical implications and future direction of, 236, 237
during exercise-induced ischemia versus spontaneous ischemia during daily life, 234-236
during mental stress, 232, 233
during nocturnal myocardial ischemia, 236
factors influencing, 230
in morning hours, role of, 230-232
in response to environmental factors, 232, 233
role of in acute cardiac events, 230
role of in myocardial ischemia, 233, 234
- Hemodynamic function, impact of anger and postanger states on, 297
- Hemorrhage(s), splinter, in infective endocarditis, 356, 432
- Hemostatic factors, as triggers of cardiovascular events, 239-248
epidemiologic data supporting the presence of, 240-243
factor VII as, 242
fibrinogen as, 240-242
fibrinolysis as, 242
future directions in study of, 247, 248
platelet activity as, 243
von Willebrand factor as, 242, 243
- circadian variation of, 243-245
effect of medication on, 245
in fibrinolytic activity, 245
in platelet reactivity, 245
effect of potential triggering activities on, 245-247
- Heparin, circadian variation in anticoagulant effect of, 258, 259
effect of on circadian variation of cardiovascular events, 245
- Hepatitis, chronic, infective endocarditis and, 329
- Histoplasma* species, in infective endocarditis, 414, 415
- "Holiday heart," 502
- Homeless men, infective endocarditis in, 354
- Human immunodeficiency virus (HIV) infection, infective endocarditis in, 417
- Hyperalimentation, infective endocarditis and, 327, 329
- Hypercholesterolemia, altered endothelial regulation of vasomotion in, 6-11
treatment and, 11-13
- Hypertension, cardiac outcome measures in, 138
need for treatment of, 132, 133
- renal outcome measures in, 138
- treatment outcome measurement in, 131-142
aortic and peripheral vascular disease as, 140
arterial compliance as, 138, 139
blood pressure as, 133, 134
cardiac events as, 140
cerebrovascular events as, 140
concomitant metabolic risk factors as, 138
controversies about, 141, 142
cost-effectiveness as, 140, 141
direct and indirect costs of treatment as, 136
evidence of clinical atherosclerosis as, 13
frequency of laboratory tests as, 136
frequency of physician visits as, 135, 136
global evaluations by patient and physician as, 136, 137
intermediate, 137-139
lifestyle modifications as, 135
long-term, 139-141
mortality as, 139
number of drugs taken as, 135
patient compliance as, 135
patient days lost from work as, 139
pros and cons of, 141
quality of life as, 134, 135
renal events as, 140
routine clinical chemistries as, 135
short-term, 133-137
symptomatic side effects as, 134
- Ibutilide, for atrial fibrillation, 515
- Immunosuppression. See also *Human immunodeficiency virus (HIV) infection*.
infective endocarditis and, 454, 455
- Inflammation, in response to coronary plaque rupture, 216, 217
role of in atherosclerosis, 212, 213
- Insect bites, infective endocarditis and, 387
- Intrauterine contraceptive device(s), infective endocarditis and, 332, 336, 337
- Intubation, infective endocarditis and, 330, 335
- Ischemia, myocardial, anger-induced, 292, 293
animal studies of, 293-299
central neuroanatomic basis of, 293, 294
human studies of, 293
role of peripheral autonomic nervous system in, 294-297
- cigarette smoking as trigger of, 278
- dreams as behavioral triggers of, 299-303
- exercise-induced, hemodynamic changes during, 234-236
- impact of anger on electrical properties of heart with, 298, 299
- mental stress as trigger of, 271-285
ambulatory electrocardiogram studies as evidence for, 276-278
clinical significance of, 282-284
evidence for, 276-280
laboratory studies of, 278-280
pathophysiology of, 280-282
prognostic significance of, 282-284
summary of characteristics of, 282
therapeutic applications of findings on, 284, 285
versus ischemia during daily life, 282
- nocturnal, hemodynamic changes during, 236
- post-stress, 297, 298
- role of hemodynamic changes in, 233, 234
- spontaneous, hemodynamic changes during, 234-236

Janeway's lesions, 356, 384, 432

Kidney(s), "flea-bitten," 435

Kidney failure, infective endocarditis and, 329

Kingella kingae, in infective endocarditis, 410, 411

Kingella species, in infective endocarditis, 354

Klebsiella species, in infective endocarditis, 354

Lactobacillus species, in infective endocarditis, 354

Legionella pneumophila, in infective endocarditis, 413, 414

Lipid(s), serum, lowering of, cost-effectiveness of, 125, 126

in reducing risk of coronary artery disease, 117-128
prognostic role of in coronary heart disease, 120, 121

Lipid disorders. See also *Lipoproteins(s)*.

cardiologist's role in detection and management of, 126-128

Lipid-lowering agents, clinical trials of, early, 121-123
recent, 123-125

using angiographic endpoints, 123

Lipoprotein(s), and thrombosis, 120

low-density, and endothelial dysfunction, 118, 119

and plaque instability, 119, 120

in smooth cell proliferation, 119

metabolism of, effect of estrogen on, 111-113

prognostic role of in coronary heart disease, 120, 121

Listeria monocytogenes, in infective endocarditis, 354, 412

Liver, biopsy of, infective endocarditis and, 331, 336

Long QT syndrome as cause of exercise-related sudden death in young athletes, 204

Magnesium, and digoxin in acute heart rate control, 526

Magnitude squared coherence spectrum, in atrial fibrillation, 499

Marfan syndrome, aortic rupture in, as cause of sudden cardiac death in young competitive athletes, 201

Markov decision model, 628

Menopause, effect of on coronary artery disease. See *Estrogen(s)*, effect of on coronary artery disease.

Metoprolol, for heart rate control in atrial fibrillation, 528, 529

Mitral valve(s), infective endocarditis in, 457-461

prolapse of, as cause of sudden cardiac death in young competitive athletes, 202, 203

infective endocarditis and, 334, 335

Morning hours, changes in hemostatic factors during, 243-245

hemodynamic changes in, role of in cardiovascular events, 230-232

Mucor species, in infective endocarditis, 414

Multicenter Investigation on the Limitation of Infarct Size (MILIS), 251, 263, 264

MULTIFIT system of risk factor modification in coronary artery disease, 143-156

clinical trial of, 146-148

implications of, 148-150

counseling to prevent smoking relapse in, 146, 147

development of, 144-146

dietary counseling in, 147

expanded clinical applications of, 154-156

factors influencing dissemination of, 150-152

financial implications of, 153, 154

home-based exercise training in, 144, 145, 147

implications of for American health care, 150-154

in management of diabetes mellitus, 155, 156

in management of heart failure, 154, 155

in management of hypertension, 155

lipid-lowering drug therapy in, 147

phone therapy in, 150

policy implications of, 152, 153

Multiple wavelet hypothesis of atrial fibrillation, 472, 473, 484

evidence for, 489-492

maze procedure as test of, 492

Murmur, heart, in infective endocarditis, 355
change in, 388

Mycoplasma hominis, in infective endocarditis, 455

Myocardial disease, as complication of infective endocarditis, 427, 428

Myocardial infarction, acute, angiographic morphology of coronary artery following, 225, 226

circadian variation in onset of, 178-183

compared with circadian pattern of efficacy of tissue-type plasminogen activator, 254, 255

in Framingham Heart Study, 179

coronary anatomy before, 221-223

day-of-the-week patterns of occurrence of, 192, 193

incidence of, 175

increased risk of during morning hours, 230-232

mental stress as trigger of, 271-285

nonfatal, risk of during heavy physical exertion, 264, 265

mechanism of, 267, 268

physical exertion as trigger of, 263-269

precipitated by anger, epidemiologic studies of, 289-292

role of plaque size and degree of stenosis in, 221-226
triggers of, 176-178

historical background on, 176-178

prevention and practical aspects of, 309-311

use of beta blockers after, in prevention of death, 190

Myocardial Infarction Onset Study, 182

Myocarditis as cause of sudden cardiac death in young competitive athletes, 202

Nafcillin, to prevent infective endocarditis, 334

Nail biting, infective endocarditis and, 335, 389

Natural disasters, as trigger of acute cardiovascular events, 275

hemodynamic changes caused by, 233

Neisseria gonorrhoeae, in infective endocarditis, 354, 405, 406

Neoplastic disease(s), infective endocarditis and, 329

Nicotine, dependency on, 56

systemic effects of, 53, 54

Nicotine gum, 59

Nicotine patch, transdermal, 58, 59

Nicotine replacement therapy, 57-59

Night terrors, impact of on heart function, 302

Nightmares, impact of on heart function, 302

Nitric oxide, in endothelial control of vasomotion, 1-13

alterations of nitric oxide synthase in
atherosclerosis and hypercholesterolemia and, 9

destruction of nitric oxide by superoxide in
atherosclerosis and hypercholesterolemia and, 9-11

intracellular signaling pathways in, 3

multifaceted roles of, 2

Northwick Park Heart Study, 240, 242

Obstetric procedure(s), infective endocarditis and, 332

- Onset Study of myocardial infarction, 264, 265
 anger scale of, 290
 Oral hygiene, infective endocarditis and, 329, 330
 Osler's nodes, 327, 356, 384, 431, 432
- Pacemaker(s), infective endocarditis and, 334, 418, 448, 449
- Pacing, to prevent atrial fibrillation, 591-595
 dual-site, 594
 mode of, 592, 593
 novel algorithms for, 595
 rate of, 594
 site of, 593, 594
- Paecilomyces* species, in infective endocarditis, 414
- Pain, musculoskeletal, in infective endocarditis, 356
- Panophthalmitis, in infective endocarditis, 356
- Parturition, infective endocarditis and, 332
- Pasteurella* species, in infective endocarditis, 409
- Pattern(s), circadian, in strokes, 179, 180
 of coronary heart disease, epidemiologic aspects of, 175-183
 pharmacologic agents affecting, 182, 183
 septadian, of acute cardiac events, 192, 193
- Penicillin(s), to prevent infective endocarditis, 333, 334
- Peptostreptococcus* species, in infective endocarditis, 412
- Pericardial disease, as complication of infective endocarditis, 429
- Periodontal disease, infective endocarditis and, 335
- Personality type as factor in anger-induced myocardial infarction, 291, 292
- Petchiae, in infective endocarditis, 356, 431
- Physician's Health Study, 245
- Plaque(s), atherosclerotic, 18-20
 composition of, 212
 in smokers versus nonsmokers, 212
 endothelial dysfunction and, effect of lipid-lowering and antioxidant therapy on, 24, 25
 rupture of, 182
 as pathologic finding in coronary artery disease, 217
 consequences of, 22
 inflammatory responses to, 216, 217
 mechanical and hemodynamic forces in, potential role of, 20-22
 pathogenetic factors for triggering and timing of, 215
 pathophysiology and inflammatory aspects of, 211-218
 pathophysiology of, 17-25
 size as factor in, 215
 stenosis severity and, 17, 18
 thrombotic response to, 215, 216
 triggering agents and, 177, 178
 vulnerability to, 18-20, 213-215
 size of, and propensity for rupture, 215
 role of in acute myocardial infarction, 221-226
 stabilization of, 17-25
 new paradigm for, 22-24
 types of, 213
 vulnerability of to rupture, 18-20, 213-215
- Plasminogen activator, tissue-type, circadian variation in, 252-258
 compared with circadian pattern of incidence of myocardial infarction, 254, 255
 implications of for chronotherapy, 259-261
 shorter time to treatment as factor in, 252, 253
- Plasminogen activator inhibitor-1, circadian variation in, 257, 258
- Platelet activity as hemodynamic risk factor, 243
- Prevotella bivia*, in infective endocarditis, 413
- Procainamide, for atrial fibrillation, 510, 511
- Progetto Lombardo Atero-Trombosi (PLAT) Study, 243
- Propafenone, for atrial fibrillation, 513, 532, 533
- Propionibacterium acnes*, in infective endocarditis, 412
- Propranolol. See also *Beta-blocking agents*.
 after myocardial infarction, prevention of death by, 190
 for heart rate control in atrial fibrillation, 524, 528, 529
- Prostate, transurethral resection of, infective endocarditis and, 331
- Prosthetic valve(s), infective endocarditis and, 327, 334, 337, 338, 386, 429, 445-448, 454
 echocardiographic detection of vegetations in, 364, 366
- Proteus* species, in infective endocarditis, 354
- Pseudallescheria boydii*, in infective endocarditis, 414, 416, 417
- Pseudomonas aeruginosa*, in infective endocarditis, 408, 416
- Psychosocial risk factors in coronary heart disease, 97-102
 interventions to reduce impact of on prognosis, 99-102
 psychopharmacologic management of, 100-102
 social support and stress-management skills in reduction of, 100
- Pulmonic stenosis, valvar, infective endocarditis and, 334
- Pyorrhea, alveolar, infective endocarditis and, 329, 330
- Q fever, infective endocarditis in, 357, 395, 411
- Quinidine. See also *Antiarrhythmic drugs*.
 for atrial fibrillation, 509-511, 624
 adverse affects of, 510
- Reentrant excitation, as mechanism of atrial fibrillation, 483, 484
 in atrial arrhythmias, 471, 472
- Reentry, anisotropic conduction and, 484-486
 as mechanism of atrial fibrillation, 483, 484
 atrial mass and, 484
 leading circle, 494, 495
 in atrial fibrillation, 471, 472
 random, 494, 495
 types of, 494, 495
- Refractory block, by antiarrhythmic drugs, 479
- Refractory period, in atrial fibrillation, 486-489
- Regurgitation, mitral, infective endocarditis and, 335
- REM sleep, coronary flow deficits during, 300, 301
- Renal disease. See also *Kidney*.
 following infective endocarditis, 435
- Reviere, Lazare, 327
- Rifampin, to prevent infective endocarditis, 334
- Rochamimaea* species, in infective endocarditis, 412, 413
- Roth spot, in infective endocarditis, 356
- Saccharomyces cerevisiae*, in infective endocarditis, 414, 415
- Salmonella* species, in infective endocarditis, 407, 408
- Schlichter's test, 396
- Scopulariopsis brevicaulis*, in infective endocarditis, 415

- Seizure(s), in infective endocarditis, 434
- Sepsis, persistent, in infective endocarditis, surgical treatment of, 452, 453
- Septadial patterns of acute cardiac events, 192, 193
- Septal defect(s). See *Atrial septal defect(s)* and *Ventricular septal defect(s)*.
- Serratia marcescens*, in infective endocarditis, 354
- Shunt(s), infective endocarditis and, arteriovenous, 329, 334
- cerebral ventriculoatrial, 334
- congenital, 334
- surgically created, 334
- Sigmoidoscopy, infective endocarditis and, 331
- Sleep, REM, coronary flow deficits during, 300, 301
- Smoker, hospitalized, management of, 60, 61
- in outpatient practice, four-step model for counseling of, 62-64
- management of, 61-64
- with or at risk of coronary heart disease, management of, 59, 60
- Smoking. See *Cigarette smoking*.
- Sotalol, for atrial fibrillation, 514, 515, 531, 532
- Spasm, coronary, as cause of exercise-related sudden death in young athletes, 204
- Splenomegaly, in infective endocarditis, 356
- Splinter hemorrhages, in infective endocarditis, 356
- Staphylococcus albus*, in infective endocarditis, 385
- Staphylococcus aureus*, in infective endocarditis, 345-347, 353, 354, 385, 399, 404, 405
- Staphylococcus epidermidis*, 334
- in infective endocarditis, 354, 385, 405
- Staphylococcus* species, in infective endocarditis, 353, 354, 404, 405
- Stenosis, aortic, valvular, sudden cardiac death in, 186
- arterial, comparison of autopsy and natural history studies with angiography in diagnosis of, 223, 224
- degree of, role of in acute myocardial infarction, 221-226
- risk of infective endocarditis in, aortic, 387
- pulmonic, 387
- Sternotrophomonas maltophilia*, in infective endocarditis, 408
- Steroid(s), infective endocarditis and, 329
- Stomach, endoscopy of, infective endocarditis and, 330
- Stomatococcus mucilaginosus*, in infective endocarditis, 413
- Streptococcus bovis*, in infective endocarditis, 385, 386
- Streptococcus equinus*, in infective endocarditis, 385, 386
- Streptococcus pneumoniae*, in infective endocarditis, 385, 403, 404
- Streptococcus* species, in infective endocarditis, 353, 385, 397-404
- group B, 400, 401
- group D, 400
- nutritionally variant, 401
- pyogenic, 398, 400
- Streptococcus viridans*, in infective endocarditis, 330, 385
- Streptomycin, to prevent infective endocarditis, 333, 334
- Stress, as trigger of acute cardiovascular events, epidemiologic evidence for, 273-276
- as trigger of plaque rupture, 177, 178
- mental. See also *Anger*.
- as trigger of myocardial ischemia and infarction, 271-285
- effect of on cardiovascular pathology, pathophysiologic model of, 272, 273
- effect of on hemostatic factors, 246, 247
- hemodynamic changes caused by, 252, 233
- myocardial ischemia following, 297, 298
- physiologic response to, 272, 273
- Stroke(s), circadian patterns in, 179, 180
- Surgery, cardiac, atrial fibrillation following, 501
- atrial flutter following, 579, 580
- infective endocarditis and, cardiac, 327, 332, 336
- major, 329
- oral, 335, 336
- Surgical lesions, effects of on atrial fibrillation and flutter, 478, 480
- Swan-Ganz catheter(s), infective endocarditis and, 329, 352
- Tachycardia, circadian rhythms in, 190
- reentry in, 471, 472
- TEE (transesophageal echocardiography). See *Transesophageal echocardiography (TEE)*.
- Teeth, procedures involving, infective endocarditis and, 329, 330
- Tetracycline, to prevent infective endocarditis, 333
- Tetralogy of Fallot, risk of infective endocarditis in, 386, 387
- Thromboembolism, in atrial fibrillation, prevention of, 537-541
- Thrombolysis, circadian variations in, 251-261
- using tissue-type plasminogen activator, 252
- Thrombolysis in Myocardial Infarction (TIMI) II Study, 251
- Thrombosis, circadian variations in, 251, 252
- evening sensitivity versus morning resistance in, 252
- Tissue-type plasminogen activator. See *Plasminogen activator, tissue-type*.
- Tonsillectomy, infective endocarditis and, 330, 335
- Tooth care in infective endocarditis, 389
- Transesophageal echocardiography (TEE), advantages and disadvantages of, 374
- bacteremia associated with, 379
- false-positive, 373
- in atrial fibrillation, 544
- and return of atrial mechanical function after cardioversion, 549, 550
- assessment of left atrial appendage function by, 545, 548, 549
- before cardioversion for, 538, 539
- cardioversion guided by, 550
- detection of left atrial thrombi by, 545-548
- predictors of success of cardioversion in, 544, 545
- spontaneous echo contrast in, 549
- in congenital heart disease, pulmonic valve vegetations in, 368
- in infective endocarditis, 330, 331, 337
- aortic valve vegetations in, 367
- detection of abscesses by, 370, 375, 379, 440, 441
- detection of valvular abnormalities and dysfunction by, 441
- detection of vegetations in, 366-372, 440
- intraoperative, 455, 456
- of prosthetic valves, 369, 448
- risk of, 418
- size of vegetations and, 378
- surgical intervention and, 453
- in the operating room, 376, 377
- negative, 372
- versus transthoracic echocardiography, 366, 368, 371, 372
- Trans-fatty acids, role of in heart disease, 72, 73
- Transplantation, risk of infective endocarditis after, 418, 419

- Transposition complexes, risk of infective endocarditis in, 386
- Transthoracic echocardiography (TTE), advantages and disadvantages of, 374
- false-positive, 373
- in atrial fibrillation, 543, 544
- in infective endocarditis, detection of abscesses by, 374, 375, 440, 441
- detection of valvular abnormalities and dysfunction by, 441
- versus transesophageal echocardiography, 366, 368, 371, 372
- Trauma, emotional. *See Stress, mental.*
- Trench fever, infective endocarditis and, 354
- Trigger(s), in angina pectoris, 180
- in sudden cardiac death, 180
- of acute cardiovascular events, environmental factors as, 232
- epidemiologic aspects of, 175-183
- hemodynamic changes as, 229-237
- hemostatic factors as, 239-248
- historical background on, 178
- mental stress as, 232
- physical activities as, 232
- prevention and practical aspects of, 309-311
- stress as, 177, 178
- of myocardial infarction, mental stress as, 271-285
- physical exertion as, 263-269
- of myocardial ischemia, dreams as, 299-303
- mental stress as, 271-285
- smoking as, 278
- of sudden cardiac death, 185-193
- dreams as, 299-303
- physical exertion as, 263-269
- Triggers and Mechanisms of Myocardial Infarction (TRIMM) study, 180, 181, 264, 265
- TTE (transthoracic echocardiography). *See Transthoracic echocardiography (TTE).*
- Urinary tract infection, infective endocarditis and, 331
- Valve(s), abnormalities of, detection of by
- transesophageal echocardiography (TEE), 441, 442
- aortic, infective endocarditis in, 456-459
- disease of, atrial fibrillation in, 501
- dysfunction of, congenital, infective endocarditis and, 334
- mitral. *See Mitral valve(s).*
- prosthetic. *See Prosthetic valve(s).*
- tricuspid, infective endocarditis in, 461-463
- Vancomycin, to prevent infective endocarditis, 333, 334, 337
- Vascular disease(s), infective endocarditis and, 329
- Vasculitis, in infective endocarditis, 384, 431
- Vasomotion, endothelial control of, altered, arginine deficiency in, 8
- destruction of nitric oxide by superoxide in, 9-11
- in atherosclerosis and hypercholesterolemia, potential mechanisms of, 7-11
- in human subjects, 6, 7
- membrane signaling alterations in, 8, 9
- nitric oxide synthase alterations in, 9
- and nitric oxide production, 1-13
- basic concepts of, 1-4
- effect of diseases on, 4-7
- future directions for clinical care in, 13
- historical perspective of, 1, 2
- hypercholesterolemia and, 7
- improvement in via treatment of hypercholesterolemia, 11-13
- risk-factor management in, 13
- Vegetation(s), in infective endocarditis, 363, 440
- and prosthetic valves, 364, 366
- defined, 425
- detection of, 363-373
- prognostic implications of detecting, 377-379
- right-sided, 364, 372, 378, 379
- size of, 377-379
- Veillonella alcalescens*, in infective endocarditis, 413
- Ventricular dysplasia, right, arrhythmogenic, as cause of sudden cardiac death in young competitive athletes, 203, 204
- as cause of exercise-related sudden death in young athletes, 204
- Ventricular septal defect(s), infective endocarditis in, 328
- risk of, 386, 387
- Verapamil. *See also Calcium-channel blockers.*
- for control of heart rate in atrial fibrillation, 524, 529-531
- von Willebrand factor as hemodynamic risk factor, 242, 243
- War as trigger of acute cardiovascular events, 274, 275
- Warfarin, in atrial fibrillation, contraindications to, 624
- versus aspirin in prevention of embolization in, 540
- Wavelength, in conceptual models of reentry in atrial fibrillation, 483
- Wolff-Parkinson-White syndrome, as cause of exercise-related sudden death in young athletes, 204
- atrial fibrillation in, 489, 490, 501, 502
- Xanthomonas maltophilia*, in infective endocarditis, 408
- Yersinia enterocolitica*, in infective endocarditis, 409